Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
1(9%)
Results Posted
117%(7 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_2
3
27%
Ph phase_3
8
73%

Phase Distribution

0

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
3(27.3%)
Phase 3Large-scale testing
8(72.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(6)
Terminated(4)

Detailed Status

Completed6
Terminated2
Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (27.3%)
Phase 38 (72.7%)

Trials by Status

terminated218%
completed655%
recruiting19%
withdrawn218%

Recent Activity

1 active trials
Showing 5 of 11
recruitingphase_2

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids

NCT05629702
withdrawnphase_2

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

NCT05974293
terminatedphase_3

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

NCT04984278
terminatedphase_3

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

NCT04203498
completedphase_3

Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

NCT04657666
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05629702Phase 2

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids

Recruiting
NCT05974293Phase 2

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

Withdrawn
NCT04984278Phase 3

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

Terminated
NCT04203498Phase 3

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

Terminated
NCT04657666Phase 3

Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

Completed
NCT01361607Phase 3

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Completed
NCT01424566Phase 3

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Completed
NCT01337089Phase 3

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Completed
NCT04592159Phase 2

Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder

Withdrawn
NCT03087201Phase 3

CANNAbinoids in the Treatment of TICS (CANNA-TICS)

Completed
NCT01262651Phase 3

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11